User discusses increased body hair after using oral minoxidil for hair loss treatment. Others share experiences and debate benefits of being hairy versus bald.
New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.
Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.
The conversation humorously discusses hair loss and subtle differences in hairlines, with references to Norwood scale stages. It satirizes the idea of asking AI for hair advice.
Hair loss is humorously blamed on ancient selection preferences, with discussions on genetics and societal norms. Treatments like finasteride are mentioned as modern solutions.
The post discusses using Carnitine Tartrate, Potassium Chloride, and Niacin to reduce hair shedding, with the user experiencing significant improvement. The user also suggests considering a ketogenic/paleo diet for those with insulin resistance-related hair loss.
The user is frustrated about not hearing any updates on the HMI-115 trial for hair loss. They are questioning if there will be any updates in the future.
Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.
Breezula (clascoterone) Phase 3 hair loss trial results are delayed, with no official updates yet. The acne version is approved, but hair loss results are still pending.
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
Clascoterone, a topical anti-androgen, is generating interest for potentially fewer systemic side effects. Users are curious about its effectiveness and details like concentration and duration of use.
Minoxidil is highly toxic to cats and dogs, even in small amounts. Users suggest switching to oral minoxidil or taking precautions to prevent pet exposure.
Minoxidil and caffeine may interact, affecting hair growth results. Users shared mixed experiences, with some noticing improvements without caffeine and others still seeing results despite coffee consumption.
Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.
Why androgenic alopecia affects the scalp rather than other body parts, potential explanations for this phenomenon, treatments available to combat hair loss, and the implications of male attractiveness in modern society.
An arthritis drug, baricitinib, is discussed as a potential treatment for autoimmune alopecia, not androgenetic alopecia. Ritlecitinib is also mentioned as a possible treatment for scarring alopecia.
Minoxidil can be harmful to pets, especially cats. Users report mixed results with hair loss stabilization but no regrowth, and suggest buying Minoxidil, finasteride, and RU58841 separately to save money.
CHK-Cu (copper peptide) and C-60 (branched carbon chain) are discussed as potentially more effective than minoxidil for hair regrowth. Some users are skeptical about the claim that DHT isn't the root cause of hair loss, and others are trying these products to see if they work.
The conversation is about a new acne treatment cream called Clascoterone Cream 1%, which is the first new mechanism of action for acne in nearly 40 years. One person joked about hoping their face will be as clean as their bald head after using the cream.
The user is experiencing hair loss, initially diagnosed as Telogen Effluvium due to stress, but is concerned it might be Androgenetic Alopecia (AGA). A suggestion was made to consider using Minoxidil or Finasteride if the condition worsens.
The conversation is about the release timeline for clinical trial results and the availability of Breezula, a hair loss treatment. The user is not comfortable buying it as a research drug from China.
A user is experiencing significant hair loss and stress, seeking advice on treatments. They are using Pura d'or shampoo and conditioner, biotin, and considering other options but are hesitant about treatments like Minoxidil due to the need for continuous use.
Han Bio plans to start Phase 1 clinical trials for a hair growth treatment in 2027 after successful results in mice. Many users express skepticism about the effectiveness of treatments that work on mice but not on humans, and discuss existing treatments like finasteride and minoxidil.
The conversation discusses a hair loss treatment formulation containing cyclosporin, minoxidil, and tacrolimus, and mentions ongoing research on hair color reversal. The treatment showed high efficacy in restoring hair color in trials with 40 to 50 people.
The conversation is about a user considering joining a clinical study for Clascoterone (Breezula) after experiencing no results with topical finasteride and minoxidil, and side effects from oral finasteride. The user is seeking advice on clinical study participation and experiences.
A user sought treatment for hair loss through Cortina Health, where they were prescribed a specific topical solution containing Finasteride, Minoxidil, and Retinoic Acid. They are unsure if this unique combination is better than generic products and are seeking advice on whether to trust Cortina Health.
A user humorously lamented spilling their minoxidil, describing it as a dramatic and personal loss. Others shared similar experiences and advised caution if pets are around.